BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or the “Company”), a clinical stage pharmaceutical company committed to developing novel therapies for age-related ...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from two Phase 2 proof-of-concept (POC) studies that investigated treatment with the ...
In the middle of the 20 th century, the field of psychology had a problem. In the wake of the Manhattan Project and in the early days of the space race, the so-called “hard sciences” were producing ...
WILMINGTON, Del.--(BUSINESS WIRE)-- Positive high-level results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI® (durvalumab) in combination with standard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results